Torrent Pharmaceuticals Ltd (IN:TORNTPHARM)
:TORNTPHARM
Want to see IN:TORNTPHARM full AI Analyst Report?
TORNTPHARM Stock Chart & Stats
₹3578.85
-₹79.35(-2.33%)
At close: 4:00 PM EST
₹3578.85
-₹79.35(-2.33%)
Day’s Range― - ―
52-Week Range₹3,139.50 - ₹4,714.50
Previous CloseN/A
Volume167.59K
Average Volume (3M)7.49K
Market Cap
₹1.55T
Enterprise Value₹1.63T
Total Cash (Recent Filing)₹10.33B
Total Debt (Recent Filing)₹28.22B
Price to Earnings (P/E)71.4
Beta0.50
Next Earnings
Jul 28, 2026EPS Estimate
15.06Next Dividend Ex-DateN/A
Dividend Yield0.84%
Share Statistics
EPS (TTM)63.23
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio5.00
Price to Book (P/B)17.02
Price to Sales (P/S)10.22
P/FCF Ratio73.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)70.8
Revenue Forecast (FY)₹195.05B
Bulls Say, Bears Say
Bulls Say
Multi-year Revenue MomentumSustained top-line growth over multiple years indicates expanding market penetration for branded generics and stronger sales execution. This durable revenue expansion supports long-term cash generation, funds reinvestment into R&D and market expansion, and reduces reliance on one-off product events.
Improved And Healthy MarginsRising net margins and stable operating margins reflect structural profitability from a branded generics model and cost control. Durably higher margins enhance free cash flow potential, provide buffer against pricing pressure, and support investment in growth areas like chronic therapy franchises.
Material Reduction In LeverageMeaningfully lower leverage improves financial flexibility for capital allocation, reduces refinancing risk, and strengthens the balance sheet to fund M&A, launches, or capex. A stronger capital structure also increases resilience to sector cyclicality and regulatory shifts in pharma markets.
Bears Say
Sharp FY2026 Asset IncreaseA very large asset increase creates uncertainty about asset composition and quality, complicating trend analysis and cash generation forecasting. Until disclosure clarifies drivers, this raises medium-term risk around impairment, working capital absorption, or one-off accounting items that affect durable fundamentals.
Uneven Cash ConversionVolatile cash conversion indicates earnings may be supported by non-cash items or working-capital swings, weakening earnings quality. Over 2–6 months this can constrain reinvestment and make free cash flow less predictable, limiting reliable funding for growth or debt reduction.
Margin Volatility / Gross Margin DropA sharp gross margin decline suggests structural mix shifts or cost pressure in key product lines or export markets. Persisting margin volatility would reduce earnings visibility and could signal intensifying competition or rising input costs that erode sustainable profitability.
Torrent Pharmaceuticals Ltd News
TORNTPHARM FAQ
What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?
Torrent Pharmaceuticals Ltd lowest stock price was ₹3139.50 and its highest was ₹4714.50 in the past 12 months.
What is Torrent Pharmaceuticals Ltd’s market cap?
Torrent Pharmaceuticals Ltd’s market cap is ₹1.55T.
When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?
Torrent Pharmaceuticals Ltd’s upcoming earnings report date is Jul 28, 2026 which is in 46 days.
How were Torrent Pharmaceuticals Ltd’s earnings last quarter?
Torrent Pharmaceuticals Ltd released its earnings results on May 22, 2026. The company reported ₹12.8 earnings per share for the quarter, missing the consensus estimate of ₹20.189 by -₹7.389.
Is Torrent Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd pays a Notavailable dividend of ₹9 which represents an annual dividend yield of 0.84%. See more information on Torrent Pharmaceuticals Ltd dividends here
What is Torrent Pharmaceuticals Ltd’s EPS estimate?
Torrent Pharmaceuticals Ltd’s EPS estimate is 15.06.
How many shares outstanding does Torrent Pharmaceuticals Ltd have?
Torrent Pharmaceuticals Ltd has 338,431,850 shares outstanding.
What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?
Torrent Pharmaceuticals Ltd reported an EPS of ₹12.8 in its last earnings report, missing expectations of ₹20.189. Following the earnings report the stock price went up 0.297%.
Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:TORNTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited operates as a global pharmaceutical entity, managing the entire process from the discovery and development of generic drug formulations to their production and distribution. Its commercial activities extend across key markets such as India, the United States, Germany, and Brazil, alongside various other international territories. The company boasts a broad product catalog, offering treatments for a wide array of medical conditions. This includes therapies for cardiovascular diseases, central nervous system disorders, gastrointestinal issues, women's health concerns, diabetes, pain management, gynecological ailments, oncology, and anti-infective medications. Additionally, Torrent Pharma supplies essential vitamins, minerals, and other nutritional supplements. Beyond its proprietary offerings, the firm also provides contract manufacturing services to other companies. During the COVID-19 pandemic, it demonstrated its commitment by securing licensing agreements for crucial treatments like Baricitinib, Molnupiravir, and Paxlovid. Established in 1959, the company originally operated under the name Trinity Laboratories before officially becoming Torrent Pharmaceuticals Limited in 1971. Its corporate headquarters are located in Ahmedabad, India. Ultimately, Torrent Pharmaceuticals Limited functions as a subsidiary of Torrent Investments Private Limited.
Technical Analysis
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Mankind Pharma Ltd.
―
Sun Pharmaceutical Industries Limited
―
Zydus Lifesciences Limited
―